Search clinical trials for: brivaracetam (BRV) tablet

Total 8152 results

UCB Biopharma SRL

Recruiting

A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants

Healthy Study Participants

Japan
UCB Pharma SA

Completed

Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy

Epilepsy

United States, Belgium, Czechia, France, Germany, Hungary, Ireland, Italy, Mexico, Poland, Spain, United Kingdom
Overseas Pharmaceuticals, Ltd.
GX pharma technology (beijing) Co., Ltd

Active, not recruiting

An Open Label, Balanced, Randomized, 3×3 Latin Square Design Comparing of Brivaracetam Sustained-release Tablets and Brivaracetam Tablets in the Oral Comparative Pharmacokinetic(PK) Study in Chinese Healthy Adult Subjects Under Fasting Conditions.

Partial Seizure

China
Centre hospitalier de l'Université de Montréal...
UCB Pharma

Completed

Brivaracetam: a Prospective and Multicentre Post-marketing Observational Study

Epilepsy

Canada
UCB Biopharma SRL

Completed

A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Male Japanese Study Participants

Healthy Study Participants

Japan
UCB Biopharma SRL

Terminated

A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures

Electroencephalographic Neonatal Seizures

Belgium, France, Germany, Ireland, United Kingdom, Czechia, Italy
UCB Pharma SA

Completed

Comparison of Brivaracetam Oral Tablet (10 mg, 50 mg, 75 mg and 100 mg) and Brivaracetam Injection (100 mg) in Healthy Volunteers

Healthy Volunteers

Netherlands
UCB Pharma

Completed

Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults

Unverricht-Lundborg Disease

United States, Canada, Finland, France, Israel, Russian Federation, Serbia, Tunisia
Tasly Pharmaceutical Group Co., Ltd

Completed

Study of Jitongning Tablet to Treat Spondyloarthritis

Spondyloarthritis

China
UCB Biopharma SRL

Active, not recruiting

A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

Epilepsy

United States, Hungary, Italy, Japan, Mexico, Poland, Spain
UCB Biopharma SRL

Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy (EXPAND)

Childhood Absence Epilepsy | Juvenile Absence Epilepsy

United States, Australia, Georgia, Italy, Poland, Romania, Slovakia, Spain, Ukraine, Belgium
UCB Biopharma SRL

Not yet recruiting

A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Childhood Absence Epilepsy | Juvenile Absence Epilepsy
UCB Pharma

Completed

Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy

Epilepsy

United States, Czechia, Germany, Poland
UCB Biopharma SRL

Enrolling by invitation

A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Childhood Absence Epilepsy | Juvenile Absence Epilepsy

United States, Georgia, Italy, Romania, Ukraine, Slovakia, Spain
UCB Pharma

Completed

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

Epilepsy

United States, Australia, Canada, Brazil, Mexico
UCB Pharma SA

Completed

Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults

Unverricht-Lundborg Disease

France, Italy, Sweden, Finland, Netherlands, Tunisia, Réunion
UCB Pharma

Completed

Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy

Epilepsy

United States, Austria, Belgium, Canada, Czechia, Finland, France, Germany, Hong Kong, Hungary, Israel, Italy, Korea, Republic of, Netherlands, Norway, Poland, Russian Federation, Serbia, Singapore, South Africa, Spain, Sweden, Swit... and more
Janssen Research & Development, LLC

Completed

Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets

HIV-1

United States
UCB BIOSCIENCES, Inc.
PRA Health Sciences

Terminated

Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures

Nonconvulsive Electrographic Seizures

United States
University of Minnesota

Recruiting

Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Neuropathic Pain | Spinal Cord Injuries

United States
UCB Biopharma SRL

Completed

A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects

Healthy Participants

China
Yiling Pharmaceutical Inc.

Completed

A Single-dose Study to Investigate the Tolerance and Pharmacokinetics of Finamine Tablets in China

Parkinson Disease

China
UCB Pharma

Completed

An Open-Label Interaction Study to Look at the Effects of Brivaracetam on Phenytoin When Taken Together in 15 Adult Patients With Epilepsy.

Epilepsy

United States
The National Institutes of Pharmaceutical R&D Co...

Completed

A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects

Idiopathic Pulmonary Fibrosis

United States
Sunshine Lake Pharma Co., Ltd.

Completed

The Tolerability , Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Adult Subjects

Nonalcoholic Steatohepatitis (NASH)

China
Atridia Pty Ltd.

Completed

A Trial of HRS-7085 Tablet in Healthy Participants With and Without Food Effect.

Inflammatory Bowel Disease

Australia
UCB Pharma

Terminated

A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

Epilepsy

United States, Belgium, Canada, Germany, Sweden, Czechia, Australia
Harmony Biosciences, LLC

Active, not recruiting

A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

Prader-Willi Syndrome

United States
Lexicon Pharmaceuticals

Completed

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
University of Rochester

Recruiting

Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas

Brain Tumor

United States
Rigshospitalet, Denmark

Completed

The Association Between Hyponatremia and Osteoporosis in Patients With Epilepsy.

Hyponatremia | Metabolic Bone Disease

Denmark
Paratek Pharmaceuticals Inc

Active, not recruiting

Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

Mycobacterium Infections, Nontuberculous | Nontuberculous Mycobacterial Lung Disease | Mycobacterium Abscessus Infection | Nontuberculous Mycobacterial Pulmonary Infection

United States
Duke University
American Heart Association

Terminated

Pacing Affects Cardiovascular Endpoints in Patients With Right Bundle-Branch Block (The PACE-RBBB Trial) (PACE-RBBB)

Heart Failure | Right Bundle-Branch Block

United States
UCB Pharma SA

Completed

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

Epilepsy

Belgium, Finland, France, Germany, Hungary, India, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom
Dong Wha Pharmaceutical Co. Ltd.

Completed

The Phase I Clinical Study to Evaluate the Pharmacokinetics of Dw1029M in Healthy Male Volunteer

Diabetic Kidney Disease

Korea, Republic of
UCB Pharma

Completed

A Study of Brivaracetam in Subjects With Partial Onset Seizures

Epilepsy, Focal

France, Poland, United Kingdom, Belgium, Germany, Spain, Czech Republic, Finland, Netherlands
UCB Pharma

Completed

Effect of Brivaracetam in Photosensitive Epileptic Subjects

Epilepsy

France, Germany
Sinew Pharma Inc.

Completed

Phase I Pharmacokinetic Study of HUYPS-1 in Healthy Volunteers

Nonalcoholic Steatohepatitis

Taiwan
Hansoh BioMedical R&D Company

Not yet recruiting

A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women

Vasomotor Symptoms

China
Aveiro University

Completed

Table to Tablet (T2T): A Novel Intervention Framework for Children With Speech Sound Disorders

Speech Disorders

Portugal
UCB PHARMA Inc. (US)

Completed

This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment

Epilepsy

United States, Australia, Brazil, Canada, India, Mexico
UCB Biopharma SRL

Enrolling by invitation

A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization

Epilepsy | Partial Seizures With or Without Secondary Generalization

China, Japan
UCB Pharma

Completed

A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.

Epilepsy

United States, Mexico, India, Brazil
UCB Pharma SA

Completed

Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy

Epilepsy

Ukraine, Belgium, Germany, Hong Kong, India, South Africa, Taiwan, Sweden, Korea, Republic of, Singapore, Russian Federation, Austria, Italy, Norway, Czechia
Fulcrum Therapeutics

Completed

Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets

Healthy Adult Subjects

United States
Boryung Pharmaceutical Co., Ltd

Withdrawn

A Study to Compare the Pharmacokinetics and Safety/Tolerability of BR-UPS (Ulipristal Acetate) 5 mg Tablet With Inisia (Ulipristal Acetate) 5 mg Tablet

Uterine Myoma

Korea, Republic of
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy

Epilepsy | Partial Seizures With or Without Secondary Generalization

China, Japan, Malaysia, Philippines, Singapore, Taiwan, Thailand
UCB Pharma

Completed

A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)

Neuralgia, Postherpetic

Poland, United Kingdom, Belgium, Spain, Bulgaria, Germany, Serbia, France, Slovakia, Czechia
UCB Pharma

Terminated

A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

Epilepsy

United States, France, Germany, Spain, Hungary, Italy
UCB Pharma SA

Completed

Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy

Epilepsy

United States, France, Germany, Spain

3

Subscribe